Huawei Technologies will immediately lose access to updates to the Android operating system, a source close the matter told Reuters.Technologyread more
Trump's threat, posted on Twitter, comes amid rising international tensions in the Middle East as the U.S. has dispatched a carrier strike group and bomber task force to the...Politicsread more
Stocks in Asia were mostly higher on Monday amid rising tensions between the U.S. and China.Asia Marketsread more
Current geopolitical tensions are making it harder and harder for oil-producing nations to make decisions that will help stabilize crude prices, Russian Energy Minister...Oilread more
Russian Energy Minister Alexander Novak said there were different options available for OPEC and its oil-producing allies in the second half of 2019, including a possible...Oilread more
Huawei is developing its own operating system for smartphones and laptops, but the company says it would only be used in "extenuating circumstances."Technologyread more
The Australian Electoral Commission (AEC) on Monday said Morrison's coalition has won 75 seats in Australia's parliament, one seat short of a 76-seat majority.Electionsread more
U.S. President Donald Trump said his tariffs on Chinese goods are causing companies to move production out of China to Vietnam and other countries in Asia, and added that any...World Politicsread more
SoftBank founder Masayoshi Son speaks in futuristic terms about his company, but the success of his late-stage VC fund is still unknown.Technologyread more
Reports of Tesla vehicles spontaneously catching fire could make customers wary of EVs just as the industry ramps up production plans.Autosread more
Amazon's large and flashy investments stand out from those of its tech peers over the past year.Technologyread more
Shares of Regeneron were down about 3 percent after the U.S. Food and Drug Administration approved the company's cholesterol-lowering drug Praluent on Friday.
The company's stock was halted at around 2 p.m. on Friday for news pending and was down 2.62 percent when halted. Shares of the company resumed trading at 3:40 p.m. ET and have risen over 30 percent in 2015 and nearly 80 percent in the last year.
The FDA said in a release the drug is "the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors."
"Praluent provides another treatment option for patients with [heterozygous familial hypercholesterolemia] or with known cardiovascular disease who have not been able to lower their [low-density lipoprotein] cholesterol enough on statins," John Jenkins, director of the Office of New Drugs at the Center for Drug Evaluation and Research, said in the release.
The FDA added it approved the drug after conducting five placebo-controlled trials where 2,476 participants were exposed to Praluent.
"Participants taking Praluent had an average reduction in LDL cholesterol ranging from 36 to 59 percent, compared to placebo," the agency said.
Some of the more common side effects of the drug include itching, swelling, pain and flu, it added.